Evidence map›Paper›PMID 39640586›Full record

ArticleiScience2024

Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC.

Junzhu Xu, Haitao Wang, Chi Zhang, Su-Han Jin, Xiaofei Chen, Fangya Tan, Benjamin Frey, Markus Hecht, Jian-Guo Sun, Udo S Gaipl and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junzhu XuDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, P.R. China.
Haitao WangThoracic Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Chi ZhangDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, P.R. China.
Su-Han JinDepartment of Orthodontics, Affiliated Stomatological Hospital of Zunyi Medical University, Zunyi, China.
Xiaofei ChenOncology Biometrics, AstraZeneca, Gaithersburg, MD 20850, USA.
Fangya TanHarrisburg University of Science and Technology, Harrisburg, PA 17101, USA.
Benjamin FreyTranslational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Markus HechtDepartment of Radiotherapy and Radiation Oncology, Saarland University Medical Center, Homburg, Germany.
Jian-Guo SunCancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China.
Udo S GaiplTranslational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Hu MaDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, P.R. China.
Jian-Guo ZhouDepartment of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy showed synergy with immunotherapy, yet the comparative effectiveness of combining immunotherapy (iRT) or chemotherapy (CRT) after platinum therapy failure in advanced non-small cell lung cancer (NSCLC) remains unexplored. We analyzed 163 patients (iRT:

Indexed as

CancerPublic health

Identifiers

PMID39640586
PMCPMC11617966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.